A screen of microbial-derived products using a 3D model of the human airway epithelium (bronchospheres) revealed flagellin (FLG) as a potential regulator of mucociliary structure and function. Flagellin, a TLR5-agonist, is the key protein component of bacterial flagella expressed by a number of organisms including Pseudomonas aeruginosa. Considering that mucus plugs in the airways of many cystic fibrosis (CF) patients would be reasonably expected to contain FLG, the epithelium is likely to be chronically exposed to this bacterial protein.
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is based in the UK with offices at the Sussex Innovation Centre.
- Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001June 14, 2021 - 9:00 am
- Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by RocheOctober 7, 2020 - 7:02 am
- Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002August 17, 2020 - 9:00 am
- Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical OfficerFebruary 10, 2020 - 9:00 am
Follow Us On Twitter
We are pleased to announce the start of Phase I clinical trials for our novel #cysticfibrosis therapy ETD001. ETD001 is an ENaC ion channel inhibitor with best-in-class potential, aimed at treating all people with #CF.
Read more: https://bit.ly/3iE0aNv